Related references
Note: Only part of the references are listed.Diagnosis and Treatment of Parkinson Disease A Review
Melissa J. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data
Dag Nyholm et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Emerging therapies in Parkinson disease - repurposed drugs and new approaches
Ahmad Elkouzi et al.
NATURE REVIEWS NEUROLOGY (2019)
Kinetics of Melanin Polymerization during Enzymatic and Nonenzymatic Oxidation
Sayan Mondal et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
Advances in Parkinson's Disease: 200 Years Later
Natalia Lopez-Gonzalez Del Rey et al.
FRONTIERS IN NEUROANATOMY (2018)
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease
Belinda Cruse et al.
NPJ PARKINSONS DISEASE (2018)
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
Ahmed A. Othman et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration
Hong-yun Wang et al.
ACTA PHARMACOLOGICA SINICA (2016)
24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease
Lucia Ricciardi et al.
MOVEMENT DISORDERS (2016)
Levodopa therapy for Parkinson disease A look backward and forward
Peter A. LeWitt et al.
NEUROLOGY (2016)
24 h Levodopa-carbidopa intestinal gel may reduce falls and unresponsive freezing of gait in Parkinson's disease
Florence C. F. Chang et al.
PARKINSONISM & RELATED DISORDERS (2015)
Novel Formulations and Modes of Delivery of Levodopa
Werner Poewe et al.
MOVEMENT DISORDERS (2015)
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Final 12-Month, Open-Label Results
Hubert H. Fernandez et al.
MOVEMENT DISORDERS (2015)
Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients
Dag Nyholm et al.
AAPS JOURNAL (2013)
Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
Substantia Nigra and Parkinson's Disease: A Brief History of Their Long and Intimate Relationship
Martin Parent et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2010)
Oxidation of carbidopa by tyrosinase and its effect on murine melanoma
Beata Gasowska-Bajger et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)